Selenium is an essential trace element shown to reduce the incidence of a wide variety of cancer types in experimental animal models. While selenium status has been observed to be inversely associated with the risk of prostate cancer, randomized controlled studies have not revealed any consistent benefit of selenium supplementation in reducing the disease. 1 Most of the biological consequences of selenium intake are considered to be mediated by its role as a constituent of selenium-containing proteins. One of these, SELENOF (previously referred to as Sep15) was originally identified as a human T cell 15 kDa protein that was labeled with Se 75 and was expressed at high levels in the prostate. 2, 3 It belongs to the family of seleniumcontaining proteins, that is, selenoproteins, in which selenium is inserted co-translationally in response to a UGA codon in the corresponding mRNA. 4 The molecular insertion of selenocysteine is determined by sequences in the 3′-untranslated region (3′-UTR) of the mRNA referred to as a SECIS (selenocysteine insertion sequence) element. 5, 6 The SELENOF gene is polymorphic in the 3′-UTR at positions 811 and 1125, a region that is critical for the recognition of UGA codons as the amino acid selenocysteine. 2 We have shown that these genetic variations are functional and contribute to determining the amount of SELENOF protein made as a function of selenium availability. 3, 7 Focusing on these polymorphisms to investigate genetic changes that occurred prior to or during cancer development, we reported that there was loss of heterozygosity (LOH) at the SELENOF locus in breast cancers and cancers of the head and neck among African Americans, but not Caucasians. 7 Several other studies have also indicated an association between genetic variants of SELENOF and the risk of colorectal cancer 8, 9 while the knockout of SELENOF has been shown to inhibit the in vitro growth and in vivo tumorigenicity and metastasis of human colon cancer cells, 10, 11 and to protect mice against chemically induced aberrant crypt foci. 12 While the function of SELENOF remains unresolved, it has been reported to reside in the endoplasmic reticulum (ER) and to associate there with the UDPglucose:glycoprotein glucosyltransferase (UGTR), likely playing an important role in disulfide bond formation and protein quality control in that organelle. [13] [14] [15] [16] SELENOF is unusual in that it contains an ERlocalization sequence but does not contain an ER-retention signal, and retention of SELENOF in the ER has been postulated to occur due to its interaction with UGTR. 13 In 2010, Penney et al 17 reported that there was a statistically significant association between polymorphisms in the gene for SELENOF, plasma selenium levels and importantly, prostate cancer mortality, but not risk. In this study, polymorphisms previously shown as functional, (forming a haplotype such that a C at residue 811 always corresponded to a G at 1125 and a T at 811 always corresponded with an A at 1125) were associated with prostate cancer-specific mortality with marginal significance (P = 0.10). The population examined in this nested case-control study consisted of self-reported Caucasians obtained from the Physicians Health Study, and the allele frequency for the 811 AA genotype was 4.8% for cases of prostate cancer (n = 1195) and 4.6% for controls (n = 1186), in good agreement with the low frequency we previously reported among Caucasians. 7 In contrast, the frequency we reported for African Americans for the AA genotype was much higher at 31%. 7 To evaluate whether racial disparity in prostate cancer incidence and outcomes may involve racespecific differences in SELENOF levels, we investigated the involvement of SELENOF in prostate cancer using cultured cells and human prostate cancer tissue microarrays, DNA samples, and human data. 
| Selenium levels
Selenium levels in plasma were determined using a Pinaacle 900T 2.7 | Identification and recruitment of subjects of the adiposity and outcomes of clinically localized prostate study cohort 
| Pathologic staging
Immediately after surgical removal (or at the time of extraction for robotic prostatectomy), the prostate gland was placed into sterile saline and delivered to the medical facility's pathology department.
The entire surface of the prostate was inked using distinct colors for the left and right lobes. The apex and base were amputated at a thickness of 2-3 mm, and subsequently cut in sagittal sections and submitted in entirety in paraffin embedding. The remaining prostate was sectioned at 3 mm intervals, creating parallel transverse sections perpendicular to the long axis. Every other slice was submitted for microscopic evaluation, with the remaining specimens retained for further study. Following institutional reporting, slides for each subject were submitted to a single pathologist for review, with pathologic findings reported consistent with published recommendations. 21 Histologic grade was reported according to the Gleason grading system, 22 and Gleason sum groups were defined as 2-6 (group 1), 7(3 + 4) (group 2), 7 (4 + 3) (group 3), 8 (group 4), and 9-10 (group 5). 23 Anatomic stage/prognostic group (I, IIA, IIB, III, and IV) was reported according to the American Joint Committee on Cancer, 7th edition. 24 
| Follow-up
Post-operatively, subjects were instructed to follow-up with the treating urologist with a serum PSA test every 3 months for the first year, every 3-6 months the second year, and annually thereafter.
Alterations to the follow-up protocol were allowed at the discretion of the treating clinician. Serum PSA measurements were performed using the Tandem PSA monoclonal antibiotic assay (Hybritech, San Diego, CA). Treatment failure within 2 years was defined as detectable (≥0.1 ng/mL) and subsequently rising serum PSA ("biochemical failure") or receipt of androgen deprivation therapy post-operatively for high progression-risk disease. Figure S1 ). Relatively high levels of expression were observed, consistent with the levels previously reported. 25 In order to verify the specificity of the antibody used for these and subsequent studies, we generated a doxycycline inducible SELENOF expression construct that was introduced into the MCF-7 cell line which does not 
| Statistical analysis

| Lower SELENOF levels in tumor tissue derived from African Americans than tissue from Caucasian men
We previously reported an approximately fivefold higher frequency of a functional polymorphism in the 3′-UTR of the SELENOF mRNA DNA samples were genotyped to determine allelic identity at both the SELENOF locus as well as for polymorphisms in the gene for the SELENOP selenium carrier protein, previously shown to be associated with the risk for advanced prostate cancer. 27 The allele frequencies are presented in Table 1 . A significant difference in the distribution in SELENOF allele frequencies for position 1125 was observed between African Americans and Caucasians, with the TT homozygous allele being 10 times more frequent in African Americans, an even greater difference than we previously reported in another cohort comprised of cancer-free individuals in the Chicago area. 7 It is noteworthy that this genotype is expected to result in lower levels of the SELENOF protein and our analysis of the TMAs described above indicated a much lower level of SELENOF protein in prostatic tissue obtained from African Americans as compared to Caucasians. Significant racial differences in allele frequencies for the SELENOP polymorphisms were not detected (Table 1 ).
3.6 | Gleason sum group positively associates with serum selenium levels and negatively associates with SELENOF genotype after accounting for SELENOF genotype (Table 2 ). In contrast, the SELENOF CC genotype was associated with a fivefold decrease in the odds of a higher Gleason sum group after accounting for serum selenium concentration (P = 0.0018).
3.7 | Treatment failure within 2 years after surgery positively associates with the serum selenium SELENOP rs3877899 AA genotype
We next searched for associations between serum selenium levels and polymorphisms in the selenium carrier protein, SELENOP, previously linked to cancer risk. The rs3877899 polymorphism results in either an alanine or threonine at position 284 of the protein with the threonineencoding allele associated with higher tissue selenium levels while the alanine-encoding allele was associated with lower breast cancer incidence and higher levels of anti-oxidant proteins. 28, 29 A significant association of selenium and SELENOP rs3877899 was found for risk of treatment failure within the first two years after surgery ( A somewhat unexpected result was that higher pre-prostatectomy serum selenium levels were significantly associated with higher tumor grade, an indication of an increased likelihood of recurrent disease following prostatectomy. These results are consistent with the possibility of an association between the frequency of polymorphisms in the selenium carrier protein SELENOP, which has been linked to higher selenium status, 30 and adverse outcome.
While selenium intake and serum/plasma levels have been associated with reduced prostate cancer risk, 1 increased prostate cancer incidence was observed among men with high baseline selenium levels who were supplemented with selenomethionine in the SELECT randomized clinical trial. 31 It is therefore conceivable that higher dietary selenium intake through the course of a lifetime may be beneficial but higher selenium status later in life, as with men participating in the SELECT trial, may be associated with increased risk of prostate cancer recurrence after prostatectomy and perhaps more aggressive disease. This notion is consistent with the results presented herein which included older participants who had undergone prostatectomy.
Prostate cancer is disproportionally greater for African American men who have both the highest incidence and mortality as compared Gleason sum = 2-6 (group 1), 7 (3 + 4) (group 2), 7 (4 + 3) (group 3), 8 (group 4), and 9-10 (group 5) . b Defined as a detectable (≥0.1 ng/mL) and rising serum PSA or receipt of additional therapy (n = 32). to other racial groups. 32 The reasons for this disparity are likely multi- 
